India, Nov. 25 -- Glenmark Pharmaceuticals has introduced Nebzmart® GFB Smartules® and Glenmark Airz® FB Smartules®, the world's first nebulized, fixed-dose triple therapy for Chronic Obstructive Pulmonary Disease (COPD).
The new products combine Glycopyrronium, Formoterol and Budesonide to reduce airway obstruction and inflammation, while improving lung function and symptom control. Delivered through an easy-to-use nebulized format, the therapy simplifies treatment for COPD patients who face challenges using MDIs or DPIs.
Mr. Alok Malik, President & Business Head – India Formulations, said the launch reflects Glenmark's commitment to advancing affordable and accessible respiratory care.
Clinical studies in India sh...